CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors
Munich, Germany and San Francisco, USA, April 29, 2026 – CatalYm today announced the appointment of seasoned biotech executive Christian S. Schade as Chairman of the Board of Directors. With over 30 years of executive leadership experience across private and public biopharma companies, Mr. Schade will provide board leadership at a crucial stage for the company, […]
CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First Patient Dosed
Trial will evaluate visugromab’s potential to reverse cancer-associated weight loss and muscle wasting by targeting GDF-15 in patients with advanced solid tumors Fourth Phase 2b study of visugromab broadens CatalYm’s late-stage development program into severe cancer-associated condition impacting treatment outcomes Munich, Germany and San Francisco, USA, April 23, 2026 – CatalYm today announced that the first patient has […]
SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT)
TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and clinically meaningful improvements in PROMIS-PF and other patient -relevant functional measures Rapid onset and significant functional improvement observed Short-course regimen demonstrated sustained and durable clinical […]
CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma
Study targets patients with unresectable or metastatic hepatocellular carcinoma who have progressed following first-line anti-PD-(L)1-based therapy Initiation of the third Phase 2b study of visugromab, expanding development into hepatocellular carcinoma following first and second-line NSCLC programs Munich, Germany and San Francisco, USA, April 7, 2026 – CatalYm today announced that the first patient has been dosed in […]
Primmune Therapeutics Appoints Chief Medical Officer and Executive Board Chair; Establishes Melanoma Clinical Study Advisory Board
Leadership additions strengthen clinical excellence and governance as the company enters its next phase of growth Primmune Therapeutics, Inc., a biotech company harnessing the power of the innate immune system, today announced the appointment of Andrew Sharabi, M.D., Ph.D., as Chief Medical Officer and Chris Krueger, J.D., as Executive Chairman of its Board of Directors. […]
Bioqube Ventures strengthens leadership team with the appointment of Tessa Ceyssens as Chief Operating Officer
Bioqube Ventures, an emerging life sciences investment firm, today announces the appointment of Tessa Ceyssens as Chief Operating Officer (COO). With her arrival, Bioqube Ventures adds a seasoned senior executive to its leadership team to support the continued build-out and professionalisation of the organisation in a rapidly evolving and dynamic market. Tessa joins Bioqube Ventures […]
Primmune Therapeutics Announces Additional Close of Series B Financing
Today, Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, announced an additional close of its Series B financing round for a total of $8.6 million with participation from Bioqube Ventures, Oberland Capital and Samsara Biocapital. This close brings the total Series B raise to $23.3 million. These funds will be […]
SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
Charles “Chip” Romp and Tom Heyman join SynOx’s Board, bringing deep launch, lifecycle, and corporate development expertise as the company advances its next-generation therapy emactuzumab toward key regulatory and commercial milestones DUBLIN, IRELAND, OXFORD, UK, and PHILADELPHIA, PA — October 21, 2025 SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial […]
CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025
Median duration of response exceeded 32 months in non-squamous non-small cell lung cancer (nsqNSCLC), 28 months in urothelial cancer (UC) and 19 months in hepatocellular carcinoma (HCC), with more than half of responses ongoing at the data cut-off Majority of responders experienced deeper and longer-lasting responses when compared to prior anti-PD-1/PD-(L)1 treatment GDF-15 blockade re-sensitized […]
CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO
Visugromab combined with PD-1 inhibitor, nivolumab, more than quadrupled the rate of pathological Complete Response (pCR; 33.3% vs. 7.1%) and substantially increased Major Pathologic Response (MPR; 66.7% vs. 21.4%) rate compared to nivolumab alone Combination achieved a fourfold increase in radiologic Objective Response Rate (rORR) (60% vs. 14.3%) Visugromab + nivolumab showed good tolerability in […]